• ​​Operating revenue in 2024 was 763.7 million euros, a 7.9% decrease on 2023, mainly due to the performance of the contract development and manufacturing business ("CDMO"). This division generated (i) lower revenues from the manufacture of the COVID-19 vaccine in comparison to 2023, when ROVI (the "Company" or the "Group") had booked higher income related to the production of the "pandemic" COVID-19 vaccine; and (ii) lower revenues related to the activities carried out to prepare the plant for production of the vaccine under the agreement with Moderna.
• Sales of the specialty pharmaceutical business increased 2% to 427.5 million euros, compared to 420.2 million euros in 2023.
• Positive evolution of Okedi® (Risperidone ISM®), which had total sales of 28.8 million euros in 2024. Okedi® sales in 2024 doubled those of 2023.
• Sales of the heparin franchise (low-molecular-weight heparins (LMWH) and other heparins) slightly decreased by 1% to 248.7 million euros in 2024, mainly due to lower orders from enoxaparin partners throughout the year. However, enoxaparin sales increased 37% to 43.6 million euros in the fourth quarter of 2024 compared to the third quarter of the year, due to a greater concentration of orders from partners in the last quarter, and rose 10% in the fourth quarter of 2024 compared to the fourth quarter of 2023. Bemiparin sales increased by 2% to 96.4 million euros in 2024.
• Good performance of Neparvis®, sales of which increased by 13% in 2024 compared to 2023, rising to 51.4 million euros.
• Gross margin was 62.7% in 2024, an increase of 3.7 percentage points on 2023. This increase was mainly due to: (i) the decrease in the contribution to the manufacturing business (CDMO) of revenue relating to activities to prepare the plant to produce medicines under the agreement with Moderna, which contributed lower margins to Group sales; (ii) the increased contribution to the CDMO business by existing customers (excluding Moderna), which contributed high margins; and (iii) the increased contribution of sales of Okedi®, which likewise added high margins.
• Net profit was 136.9 million euros in 2024.
• In December 2024, for the fifth year running, ROVI improved its ESG risk rating awarded by Sustainalytics, achieving a low risk of 16.1, compared to 16.4 the previous year. The Company was placed fifth in the world ESG risk ranking from among the 424 companies evaluated in the pharmaceutical industry.
• Effective 13 September 2024, ROVI cancelled 2,780,395 treasury shares through a capital reduction and delisted them from the Stock-Exchange Interconnection System (Sistema de Interconexión Bursátil) and the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges. As a result, the share capital of ROVI is now EUR 3,074,145.72, divided into 51,235,762 ordinary shares. Consequently, the shareholders have automatically increased their percentage interest in the share capital.
• ROVI will propose to the General Shareholders' Meeting a dividend of 0.9351 euros per share entitled to receive it, charged to the 2024 profit. This would entail distribution to an amount equivalent to approximately 35% of the consolidated net profit for 2024 attributed to the parent company.

OUTLOOK
For 2025, ROVI expects its operating revenue to decrease by a mid-single-digit percentage in comparison with 2024. Notwithstanding, this guidance is calculated using certain factors that could be relevant to the estimates and that are difficult to specify at the present time. They include, among others, the following:
1. First, as of today’s date, the Company is unable to forecast how the demand and production might evolve for the vaccination campaigns that will take place in 2025.
2. Second, it is hoped that the expansion of the compounding, aseptic filling, inspection, labelling and packaging capacities at the ROVI facilities in Madrid and the current high market demand for contract manufacturing services (CDMO) will favour obtaining new business, with the resulting sales impact. This would have to be considered but is impossible to estimate at this time.